3D printing has revolutionized manufacturing by reducing costs and giving designers and engineers immense flexibility. Could 3D bioprinting do the same for biotechnology?
The 3D bioprinting field is still quite young, but it is developing rapidly. In fact, the 3D bioprinting market is expected to grow from €700M ($820M) in 2019 to a massive €4B ($4.7B) by 2027. With the interest of investors peaking, many companies in the field have recently taken strides forward in their technological development.
Over the last decade, bioprinting has generated a lot of expectations, such as 3D printing organs for transplantation or replacing animal research. Such breakthroughs may still be far from reaching the market, but 3D bioprinting has been finding more and more uses in the biomedical field.
“Recent advances and commercially available systems have propelled the technology forward and made it more accessible to researchers,” Erik Gatenholm, CEO and co-founder of Cellink, told me.
Stockholm-based Cellink is one of the biggest bioprinting companies worldwide. It recently reached a valuation of more than €840M. The company sells a wide range of equipment that allows labs to perform 3D bioprinting, focusing on tissue engineering and regenerative medicine applications.
The company is faring well despite the global pandemic and acquired the German precision dispensing company Scienion AG last August for €80M.
Published on Thu, 17 Sep 2020 12:28:02 +0000 and made possible by nintex median